A significant move in the pharmaceutical investment landscape has emerged as Carlyle-backed Abingworth seeks to raise up to £1.5 billion for clinical trials funding, marking a strategic shift towards royalty-based
A significant move in the pharmaceutical investment landscape has emerged as Carlyle-backed Abingworth seeks to raise up to £1.5 billion for clinical trials funding, marking a strategic shift towards royalty-based






